Date: 2014-10-09
Type of information: Licensing agreement
Compound: vipadenant (V2006)
Company: Vernalis (UK) RedoxTherapies (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease:
Details: * On October 9, 2014, Vernalis announced that it has licensed worldwide rights in vipadenant (V2006), a small molecule A2A receptor antagonist, to RedoxTherapies. Vipadenant has the potential to disrupt an immunosuppressive mechanism of tumor protection, generating improved efficacy for immunotherapies of certain cancers when used in combination.
Redox is a private, Boston-based start-up company that is the exclusive licensee of National Institute of Health (USA) intellectual property in the field of using extracellular adenosine receptor inhibitors in combination with immuno-oncology therapies.
Financial terms: Detailed financial terms of the Licence Agreement with Redox were not disclosed.
Latest news:
